Blocklisting Six Monthly Return

Hutchmed (China) Limited

28 June 2024

 

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ - Friday, June 28, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

1.	Name of applicant:		HUTCHMED (China) Limited
2.	Name of scheme:		Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")
3.	Period of return:		From December 29, 2023 to June 28, 2024
4.	Balance under scheme from previous return:		2015 HUTCHMED Share Option Scheme: 46,847,218 ordinary shares of US$0.1 each
5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		2015 HUTCHMED Share Option Scheme: Nil
6.	Number of securities issued/allotted under scheme during period:		2015 HUTCHMED Share Option Scheme: 103,450
7.	Balance under scheme not yet issued/allotted at end of the period:		2015 HUTCHMED Share Option Scheme: 46,743,768 ordinary shares of US$0.1 each
8.	Number and class of securities originally listed and the date of admission:		25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019)
9.	Total number of securities in issue at the end of the period:		871,359,720 ordinary shares of US$0.1 each
Name of contact:			Weiguo Su
Address of contact:			Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
Telephone number of contact:			[phone]

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries	[phone] / [e-mail]
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting	[phone] / [phone] (Mobile) / [phone] (Mobile) / [e-mail]
Zhou Yi, Brunswick	[phone] (Mobile) / [e-mail]
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon	[phone]

 

END